Edaravone: A new drug approved for ALS

Research output: Contribution to journalShort survey

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone. Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.

Original languageEnglish (US)
Number of pages1
JournalCell
Volume171
Issue number4
DOIs
StatePublished - Nov 2 2017

Fingerprint

Amyotrophic Lateral Sclerosis
Riluzole
Neurodegenerative diseases
Oxidants
Pharmaceutical Preparations
Drug Discovery
Neurodegenerative Diseases
History
phenylmethylpyrazolone

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Edaravone : A new drug approved for ALS. / Rothstein, Jeffrey D.

In: Cell, Vol. 171, No. 4, 02.11.2017.

Research output: Contribution to journalShort survey

@article{f69df8685aaf441c84416ac48dec4b13,
title = "Edaravone: A new drug approved for ALS",
abstract = "Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone. Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.",
author = "Rothstein, {Jeffrey D}",
year = "2017",
month = "11",
day = "2",
doi = "10.1016/j.cell.2017.10.011",
language = "English (US)",
volume = "171",
journal = "Cell",
issn = "0092-8674",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Edaravone

T2 - A new drug approved for ALS

AU - Rothstein, Jeffrey D

PY - 2017/11/2

Y1 - 2017/11/2

N2 - Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone. Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.

AB - Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone. Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.

UR - http://www.scopus.com/inward/record.url?scp=85032709603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032709603&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2017.10.011

DO - 10.1016/j.cell.2017.10.011

M3 - Short survey

C2 - 29100067

AN - SCOPUS:85032709603

VL - 171

JO - Cell

JF - Cell

SN - 0092-8674

IS - 4

ER -